Mutations to the BRCA1 and BRCA2 genes significantly increase the chances of breast and ovarian cancers, and a test can assess a person’s risk from those variants. But those genes are just two of the ...

– Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies – – May provide real-time data on therapy response, support patient ...

Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin ...

Invitae’s revenue has climbed over time thanks to a vast portfolio of genetic tests. At the same time, the company has struggled to turn that into profitability. Invitae shares have dropped more than ...